期刊文献+

降钙素原、超敏C反应蛋白、D-二聚体和纤维蛋白原在COPD急性加重期患者的动态变化及临床意义 被引量:25

The value of procalcitonin,high-sensitivity c-reactive protein,D-dimer,fibrinogen in acute exacerbation of chronic obstructive pulmonary disease patients
下载PDF
导出
摘要 目的探讨降钙素原(PCT)、超敏C-反应蛋白(Hs-CRP)、D-二聚体、纤维蛋白原(FIB)在慢性阻塞性肺疾病急性加重期(AECOPD)中的动态变化,以及上述指标的临床意义。方法收集62例AECOPD患者入院时、入院治疗1周后、出院前的PCT、Hs-CRP、D-二聚体、FIB水平,并收集60例COPD稳定期患者的上述指标作为对照。结果 AECOPD组患者的入院时PCT、Hs-CRP、D-二聚体、FIB水平均高于对照组,差异有统计学意义(P<0.05);AECOPD患者治疗1周后,PCT、Hs-CRP、D-Dimer、FIB的水平显著下降;至出院前,上述指标均降至最低水平(P<0.05)。结论动态监测AECOPD患者的PCT、Hs-CRP、D-二聚体、FIB的变化,对患者病情的控制、治疗效果的监测、疾病的预后等有重要的意义。 Objective To investigate the dynamic changes and clinical significance of these indicators,Procalcitonin( PCT),high- sensitivity c- reactive protein( HS- CRP),d- dimer and Fibrinogen in acute exacerbation of chronic obstructive pulmonary disease( AECOPD) patients. Methods The Hs- CRP,d- dimer,Fibrinogen level of 62 cases of chronic obstructive pulmonary disease patients were detected on admission,admission after 1 week of treatment,the PCT before discharge. At the same time,these indicators of 60 normal persons were detected and included as control group. Results AECOPD patients on admission and the admission after 1 week of treatment,discharge,a former PCT Hs-CRP,d- dimer,Fibrinogen levels were higher than those in the control group. AECOPD patients after 1 week,the PCT,Hs- CRP,D- Dimer,FIB levels decreased significantly. Before discharge,the above indexes have fallen to the lowest level( P 0. 05). Conclusion AECOPD dynamic monitoring in patients with PCT,Hs- CRP,d- dimer,Fibrinogen changes in control of the patient,the monitoring of treatment,the prognosis of the disease,which are of great significance.
作者 宣萱 李艳
出处 《临床和实验医学杂志》 2015年第3期202-204,共3页 Journal of Clinical and Experimental Medicine
关键词 慢性阻塞性肺疾病急性加重期 降钙素原 超敏C反应蛋白 D-二聚体 纤维蛋白原 Acute exacerbation of chronic obstructive pulmonary disease Procalcitonin High-sensitivity c-reactive protein D-di-mer Fibrinogen
  • 相关文献

参考文献12

  • 1Lindner G, Funk GC, Pfortmueller CA, et al. D - dimer to rule outpulmonary embolism in renal insufficiency[ J]. Am J Med, 2014,127(4):343 -347.
  • 2蓝芬,朱卫华,严琼,左斌,钟莹,陈子谓.噻托溴铵联合舒利迭治疗COPD的临床疗效观察[J].临床和实验医学杂志,2014,13(7):532-534. 被引量:18
  • 3慢性阻塞性肺疾病诊疗规范(2011年版)[J].柳州医学,2012,25(3):165-171. 被引量:5
  • 4Shi X, Li H. Anticoagulation therapy in patients with chronic obstruc-tive pulmonary disease in the acute exacerbation stage [ J ] . Exp TherMed, 2013,5(5) : 1367 -1370.
  • 5Grace E, Turner RM. Use of procalcitonin in patients with various de-grees of chronic kidney disease including renal replacement therapy[ J].Clin Infect Dis, 2014,59(12) :1761 -1767.
  • 6Pazarli AC,Koseoglu HI,Doruk S,et al. Procalcitonin: Is it a predic-tor of noninvasive positive pressure ventilation necessity in acute chronicobstructive pulmonary disease exacerbation[ J] ? J Res Med Sci, 2012,17(11):1047-1051.
  • 7Liu Y, Liu X,Lin G, et al. Decreased CD34 + cell number is correla-ted with cardiac dysfunction in patients with acute exacerbation of COPD[J]. Heart Lung Circ, 2014,23(9) ;875 -882.
  • 8蔡玉婵,魏琦,尧荣凤,李智.4项炎性指标在急性上呼吸道感染中的检测意义[J].检验医学与临床,2014,11(20):2847-2849. 被引量:12
  • 9Uzum AK, Aydin MM, Tutuncu Y, et al. Serum ghrelin and adiponec-tin levels are increased but serum leptin level is unchanged in lowweightChronic Obstructive Pulmonary Disease patients[ J]. Eur J InternMed, 2014,25(4):364 -369.
  • 10Can 0, GUzelant A, Yerlikaya FH, et al. The role of serum soluble u-rokinase - type plasminogen activator receptor in stable chronic obstruc-tive pulmonary disease[ J]. J Investig Med, 2014,62(7) :938 -943.

二级参考文献31

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8240
  • 2叶任高.内科学[M].北京:人民卫生出版社,2005.726.
  • 3Hind M, Maden M. Retinoic acid induces alveolar regeneration in the a- dult mouse lung[ J]. Eur Respir J, 2004,23 ( 1 ) ;20 - 27.
  • 4Fang Y, Xu P, Gu C, et al. Ulinastatin improves pulmonary function in severe bum - induced acute lunginjury by attenuating inflammatory re- sponse [ J ]. J Trauma, 2011,71 ( 5 ) : 1297 - 1304.
  • 5Zhang Y, Zhang B, Xu DQ, et al. Tanshinone IIA attenuates seawater aspiration - induced lung injury byinhibiting macrophage migration in- hibitory factor[ J ]. Biol Pharm Bull, 2011,34 (7) : 1052 - 1057.
  • 6Keating GM, McCormack PL. Salmeterol/flutieasone propionate: a re- view of its use in the treatment of chronic obstructive pulmonary disease [J]. Drugs, 2007,67(16) :2383 -2405.
  • 7Balkissoon R, Make B. A double - blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plusalbuterol 180 μg pm q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours inpatients with chronic obstructive pulmo- nary disease[J]. COPD, 2008,5(4) :221 -227.
  • 8Evans TW. International Consensus Conferences in Intensive Care Medi- cine: non - invasive positive pressure ventilation in acute respiratory failure. Organised jointly by the American Thoracic Society, the Euro- pean Respiratory Society, the European Society of Intensive Care Medi- cine, and the Societe de Reanimation de Langue Fran? aise, and ap- proved by the ATS Board of Directors, December 2000 [ J ]. Intensive Care Med, 2001,27 ( 1 ) : 166 - 178.
  • 9Keam SJ, Keating GM. Tiotropium bromide. A review of its use as ma- intenance therapy in patients with C OPD [ J]. Treat Respir Med, 2004, 3(4) :247 -268.
  • 10Vincken W, van Noord JA, Greefhorst AP, et al. Improved health out- comes in patients with COPD during 1 yrs treatment with tiotropium[ J]. Eur Respir J, 2002,19 (2) :209 - 216.

共引文献36

同被引文献181

引证文献25

二级引证文献155

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部